Ken Griffin Incyte Corp Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Incyte Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 114,400 shares of INCY stock, worth $7.99 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

114,400

Previous 70,000 63.43%

Holding current value

$7.99 Million

Previous $4.24 Million 78.2%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$57.33 - $68.61 $2.32 Million - $2.77 Million	-40,392 Reduced 4.92%	781,277 $51.6 Million
Q2 2024 Aug 14, 2024	BUY	$51.18 - $63.75 $26.8 Million - $33.4 Million	524,419 Added 176.42%	821,669 $49.8 Million
Q1 2024 May 15, 2024	SELL	$56.55 - $66.59 $1.94 Million - $2.28 Million	-34,312 Reduced 10.35%	297,250 $16.9 Million
Q4 2023 Feb 14, 2024	SELL	$52.16 - $64.19 $4.4 Million - $5.42 Million	-84,428 Reduced 20.3%	331,562 $20.8 Million
Q3 2023 Nov 14, 2023	SELL	$57.77 - $65.93 $81.5 Million - $93.1 Million	-1,411,423 Reduced 77.24%	415,990 $24 Million
Q2 2023 Aug 14, 2023	BUY	$60.95 - $75.51 $109 Million - $135 Million	1,793,088 Added 5223.85%	1,827,413 $114 Million
Q1 2023 May 15, 2023	BUY	$70.23 - $86.01 $2.18 Million - $2.67 Million	31,083 Added 958.76%	34,325 $2.48 Million
Q4 2022 Feb 14, 2023	SELL	$67.18 - $84.11 $2.74 Million - $3.43 Million	-40,724 Reduced 92.63%	3,242 $260,000
Q3 2022 Nov 14, 2022	BUY	$66.18 - $82.86 $2.62 Million - $3.28 Million	39,643 Added 917.03%	43,966 $2.93 Million
Q2 2022 Aug 15, 2022	SELL	$66.18 - $83.18 $73.2 Million - $92 Million	-1,106,259 Reduced 99.61%	4,323 $328,000
Q1 2022 May 16, 2022	BUY	$66.02 - $79.71 $16.9 Million - $20.4 Million	255,786 Added 29.92%	1,110,582 $88.2 Million
Q4 2021 Feb 14, 2022	BUY	$63.34 - $74.11 $25.4 Million - $29.7 Million	400,346 Added 88.09%	854,796 $0
Q3 2021 Nov 15, 2021	BUY	$68.67 - $84.02 $18.2 Million - $22.2 Million	264,452 Added 139.19%	454,450 $31.3 Million
Q2 2021 Aug 16, 2021	SELL	$79.87 - $87.53 $67.8 Million - $74.3 Million	-848,953 Reduced 81.71%	189,998 $0
Q1 2021 May 17, 2021	BUY	$76.02 - $100.5 $60.5 Million - $80 Million	795,714 Added 327.14%	1,038,951 $84.4 Million
Q4 2020 Feb 16, 2021	BUY	$80.74 - $97.7 $12.7 Million - $15.3 Million	156,875 Added 181.65%	243,237 $21.2 Million
Q1 2020 May 15, 2020	SELL	$63.18 - $85.97 $56.6 Million - $77.1 Million	-896,252 Reduced 91.21%	86,362 $6.32 Million
Q4 2019 Feb 14, 2020	BUY	$73.04 - $95.72 $52.5 Million - $68.8 Million	718,731 Added 272.37%	982,614 $85.8 Million
Q3 2019 Nov 14, 2019	BUY	$72.82 - $86.52 $4.09 Million - $4.85 Million	56,100 Added 27.0%	263,883 $0
Q2 2019 Aug 14, 2019	SELL	$73.52 - $88.7 $21.6 Million - $26.1 Million	-294,030 Reduced 58.59%	207,783 $17.7 Million
Q1 2019 May 15, 2019	SELL	$63.56 - $88.17 $112 Million - $156 Million	-1,768,282 Reduced 77.89%	501,813 $0
Q4 2018 Feb 14, 2019	BUY	$58.5 - $69.94 $38.4 Million - $45.9 Million	656,388 Added 40.68%	2,270,095 $0
Q3 2018 Nov 13, 2018	SELL	$61.75 - $74.23 $16.9 Million - $20.3 Million	-273,493 Reduced 14.49%	1,613,707 $0
Q2 2018 Aug 10, 2018	BUY	$60.85 - $83.98 $76.9 Million - $106 Million	1,264,002 Added 202.83%	1,887,200 $0
Q1 2018 May 11, 2018	BUY	$83.06 - $100.98 $12.8 Million - $15.6 Million	154,494 Added 32.96%	623,198 $51.9 Million
Q4 2017 Feb 09, 2018	SELL	$93.56 - $116.6 $1.21 Million - $1.51 Million	-12,972 Reduced 2.69%	468,704 $44.4 Million
Q3 2017 Nov 09, 2017	BUY	$109.15 - $138.27 $52.6 Million - $66.6 Million	481,676	481,676 $56.2 Million

Others Institutions Holding INCY

# of Institutions

643

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account